Progressive Down Regulation Of Jak-Stat, Cell Cycle, And Abc Transporter Genes In Cd34+/Lin- Cells Of Chronic-Phase Chronic Myeloid Leukemia (Cp-Cml) Patients At Diagnosis Vs. 12 Months Of Nilotinib Treatment Vs. Healthy Subjects

In the PhilosoPhi34 study (EudraCT: 2012-005062-34) on 87 CP-CML patients, we analyzed the gene expression profiling (GEP) of bone marrow (BM) CD34+/lin- cells of 79 patients with chronic-phase chronic myeloid leukemia (CP-CML) patients at diagnosis and after 12 months of nilotinib treatment (Pungolino et al. AM J Hematol. 2018). FISH analyses identified CD34+/lin- Ph+ cells in all 79 CML-CP patients at diagnosis. 78/79 patients achieved at least a complete cytogenetic response after 12 months of nilotinib whereas 1/79 patients relapsed at 12 months. No Ph+ nuclei were detected in 78/79 patients at 12 months.